CTOs on the Move


 
Ÿnsect is the world leader in the production of protein and natural insect fertilizers. Founded in 2011 in Paris, France, by both scientists and environmental activists, Next40 and B Corp-certified, the company processes insects into high-end, high-value ingredients for pets, fish, plants and humans. From its purpose-built state-of-the-art farms, Ÿnsect offers a long-term, sustainable, organic solution to accelerate protein and plant consumption. Ÿnsect uses pioneering proprietary technology covered by 377 patents across 44 categories, to produce lesser and yellow mealworms in fully automated vertical farms. Ÿnsect runs three production sites, one in Dole, France (commissioned 2016), one in the Netherlands ...
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Caris Life Sciences

Caris Life Sciences® (Caris) is a molecular science company developing and delivering technologies to revolutionize healthcare. The Company`s suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers improve outcomes and save lives. Caris is also advancing precision medicine through advanced artificial intelligence (AI) and machine learning algorithms. Leveraging the Company`s proprietary AI analytics engine, DEAN™, across its extensive catalog of molecular intelligence and clinical outcomes data, Caris is actively developing a better understanding of the molecular mechanisms of cancer in ways never before possible. This information provides an unmatched resource to help physicians better identify and predict patient response to therapy, as well as support researchers and biopharmaceutical companies derive unique insights for research development, clinical trials and target identification. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Denver, Tokyo, Japan and Basel, Switzerland. Caris provides services throughout the U.S., Europe, Asia and other international markets.

Sorrento Therapeutics

Sorrento is an oncology company developing new treatments for cancer and associated pain. Sorrento recently announced that NantPharma acquired the rights to Cynviloq™, which completed a successful TRIBECA study. Sorrento is also developing resiniferatoxin (RTX), a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. In December 2014, Sorrento and NantWorks formed a global joint venture, now called Nantibody, to focus on immunotherapies for cancer. Also in December 2014, Sorrento and Conkwest, Inc., a privately-held immuno-oncology company developing proprietary Neukoplast,® a Natural Killer (NK) cell-line based therapy, entered into an agreement to jointly develop CAR.TNK™ (Chimeric Antigen Receptor Tumor-attacking Neukoplast) immunotherapies for the treatment of cancer and infectious diseases. In March 2015, Sorrento entered into a global collaboration with NantCell, a NantWorks company, to discover and develop immunotherapies against tumor neo-epitopes.

Aurora Biomed

Aurora Biomed is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BenevolentAI

BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange.

Cutanix Corporation

Cutanix Corporation is a Franksville, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.